News
Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and pharmacokinetics.
See press release here.
Certificate of patent.
The LiGalli press release can be found here.
Read the article here.
Read the article here.
See press release here.
The first in-human trials will start shortly.
First in the EU, later also in the US
Watch the video on the page “How it works.”
We look forward to working with our new partner Gimix ('TwentyNext' per July 2022).
What's new
If you had to guess, which is more common in women—diabetes or endometriosis? It’s a trick question. They actually affect women equally. However, endometriosis receives $1 of research funding for every $200 invested in diabetes.
While there may be various explanations for this discrepancy, there’s a long pattern of health care providers, venture capitalists, and science…
Get in touch
Office
Leiden Bio Science Park – BioPartner 1
Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands